WHO Approves First Malaria Drug for Babies in 'Major Public Health Milestone'
The World Health Organization approves Coartem Baby, the first malaria treatment specifically designed for newborns and infants.
Science
Scientists Identify 10,000 'Impossible' Exoplanet Candidates, Potentially Tripling Known Alien Worlds
Astronomers identify approximately 10,000 previously unknown exoplanet candidates using novel data analysis methods, many in regions where traditional theory says planets shouldn’t form, potentially nearly tripling the known count.
Alzheimer's Breakthrough: Blocking a Single Protein Restores Memory in Mice
Scientists discover that blocking or boosting a single key protein can help the brain fight Alzheimer’s disease, successfully restoring memory and learning abilities in mice with advanced Alzheimer’s, opening a new direction for treatment.
California, Arizona and Nevada Announce New Colorado River Water-Saving Plan
Three southwestern US states announce a new Colorado River water conservation plan, with Nevada voluntarily cutting its own allocation to address the river’s ongoing drought crisis, offering Arizona a ’lifeline.'
Battery Recycling and Reuse Patents Surge Seven-Fold in Past Decade
The European Patent Office reports that battery recycling and reuse patents have increased more than seven-fold over the past decade, reflecting growing global demand for sustainable energy solutions.
Humpback Whale 'Timmy' Released into North Sea After Elaborate Rescue Off German Coast
A humpback whale nicknamed ‘Timmy’ that had been stranded off Germany’s coast for weeks was successfully released into the North Sea following an elaborate rescue operation.
NASA Raises Commercial Lunar Payload Services Contract Ceiling to $4.2 Billion
NASA announces it is raising the Commercial Lunar Payload Services (CLPS) contract ceiling to $4.2 billion to support the growing demand for lunar lander missions and accelerate the Artemis program.
FDA Approves Early Access to Breakthrough Pancreatic Cancer Drug, First RAS Inhibitor Shows Promise
The FDA approves expanded access to daraxonrasib, the first RAS-targeting inhibitor for pancreatic cancer, which has shown promise in extending survival for metastatic patients in clinical trials.
FDA Expands Access to Promising Pancreatic Cancer Drug daraxonrasib
The FDA has granted expanded access to Revolution Medicines’ targeted pancreatic cancer drug daraxonrasib, opening a pathway for more patients to receive a therapy that has shown promising results in clinical trials.
FDA Grants Expanded Early Access to Breakthrough Pancreatic Cancer Drug Daraxonrasib
The U.S. FDA approves expanded access to daraxonrasib, a breakthrough targeted therapy for previously treated metastatic pancreatic ductal adenocarcinoma, offering new hope for patients with one of the deadliest cancers.